ANEBAnebulo Pharmaceuticals, Inc.

Nasdaq anebulo.com


$ 3.20 $ -0.17 (-5.45 %)    

Thursday, 02-May-2024 10:05:45 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 2.95
$ 3.20
$ 0.00 x 0
$ 0.00 x 0
$ 3.20 - $ 3.20
$ 1.62 - $ 4.05
3,614
na
76.08M
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-13-2024 12-31-2023 10-Q
2 11-14-2023 09-30-2023 10-Q
3 09-22-2023 06-30-2023 10-K
4 05-11-2023 03-31-2023 10-Q
5 02-10-2023 12-31-2022 10-Q
6 11-10-2022 09-30-2022 10-Q
7 09-09-2022 06-30-2022 10-K
8 05-11-2022 03-31-2022 10-Q
9 02-11-2022 12-31-2021 10-Q
10 11-12-2021 09-30-2021 10-Q
11 09-22-2021 06-30-2021 10-K
12 06-21-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 substance-use-disorder-company-narrows-q2-net-loss-reports-progress-on-cannabinoid-intoxication-drug

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday secon...

 anebulo-pharmaceuticals-q2-eps-011-misses-010-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimat...

 anebulo-pharmaceuticals-filed-us-patent-application-20240010617-crystalline-forms-of-a-cannabinoid-receptor-type-1-cb1-modulator-and-methods-of-use-and-preparation-thereof

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240010617<p> Float: 3,912,399

 anebulo-pharmaceuticals-q1-eps-010-beats-012-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate ...

 why-servisfirst-bancshares-shares-are-trading-lower-by-6-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent...

 anebulo-pharmaceuticals-incs-richie-cunningham-announced-as-chief-executive-officer-and-member-of-anebulos-board-of-directors

- Reuters

 benchmark-reiterates-speculative-buy-on-anebulo-pharmaceuticals-maintains-8-price-target

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 ...

 on-september-26-2023-anebulo-pharmaceuticals-appointed-daniel-george-as-the-companys-part-time-cfo-principal-financial-officer-and-principal-accounting-officer-effective-september-28-replacing-sandra-gardiner---8k

https://www.sec.gov/ix?doc=/Archives/edgar/data/1815974/000149315223034696/form8-k.htm

 hc-wainwright--co-reiterates-buy-on-anebulo-pharmaceuticals-maintains-6-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy and maintains...

 maxim-group-initiates-coverage-on-anebulo-pharmaceuticals-with-buy-rating-announces-price-target-of-6

Maxim Group analyst Michael Okunewitch initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and ann...

 anebulo-pharmaceuticals-q4-eps-010-beats-012-estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate ...

 hc-wainwright--co-initiates-coverage-on-anebulo-pharmaceuticals-with-buy-rating-announces-price-target-of-6

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy ra...

 on-august-29-anebulo-pharmaceuticals-incs-sandra-a-gardiner-notified-company-of-her-resignation-as-cos-acting-cfo

- Reuters

 anebulo-receives-positive-feedback-from-fda-on-path-to-phase-3-trial-of-its-drug-for-acute-cannabinoid-intoxication

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive feedback from the United States Food and Drug Administration fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION